Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents
{{output}}
Cancers with wild-type BRCA, homologous recombination proficiency, or de novo or acquired resistance to PARP inhibition represent a growing population of patients who may benefit from combinatorial PARP inhibitor strategies. We review targeted inhibitors of an... ...
